{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:40:18Z","timestamp":1761709218477},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T00:00:00Z","timestamp":1461196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s11899-016-0322-5","type":"journal-article","created":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T10:03:54Z","timestamp":1461233034000},"page":"224-233","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides"],"prefix":"10.1007","volume":"11","author":[{"given":"Meenal","family":"Kheterpal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Mehta-Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Virmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia L.","family":"Myskowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven M.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,21]]},"reference":[{"issue":"10","key":"322_CR1","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","volume":"105","author":"R Willemze","year":"2005","unstructured":"Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768\u201385.","journal-title":"Blood"},{"issue":"5","key":"322_CR2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/DAD.0b013e31818118f7","volume":"30","author":"AV Morales","year":"2008","unstructured":"Morales AV, Arber DA, Seo K, Kohler S, Kim YH, Sundram UN. Evaluation of B-cell clonality using the BIOMED-2 PCR method effectively distinguishes cutaneous B-cell lymphoma from benign lymphoid infiltrates. Am J Dermatopathol. 2008;30(5):425\u201330.","journal-title":"Am J Dermatopathol"},{"key":"322_CR3","doi-asserted-by":"crossref","unstructured":"Fujiwara M, Morales AV, Seo K, Kim YH, Arber DA, Sundram UN. Clonal identity and differences in primary cutaneous B-cell lymphoma occurring at different sites or time points in the same patient. Am J Dermatopathol. 2013;35(1):11\u20138.","DOI":"10.1097\/DAD.0b013e318255dbae"},{"issue":"1","key":"322_CR4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1525-1578(10)60609-5","volume":"2","author":"M Nihal","year":"2000","unstructured":"Nihal M, Mikkola D, Wood GS. Detection of clonally restricted immunoglobulin heavy chain gene rearrangements in normal and lesional skin: analysis of the B cell component of the skin-associated lymphoid tissue and implications for the molecular diagnosis of cutaneous B cell lymphomas. J Mol Diagn. 2000;2(1):5\u201310.","journal-title":"J Mol Diagn"},{"issue":"2","key":"322_CR5","first-page":"315","volume":"119","author":"M Kadin","year":"1985","unstructured":"Kadin M, Nasu K, Sako D, Said J, Vonderheid E. Lymphomatoid papulosis. A cutaneous proliferation of activated helper T cells expressing Hodgkin's disease-associated antigens. Am J Pathol. 1985;119(2):315\u201325.","journal-title":"Am J Pathol"},{"issue":"12","key":"322_CR6","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","volume":"95","author":"MW Bekkenk","year":"2000","unstructured":"Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95(12):3653\u201361.","journal-title":"Blood"},{"issue":"5","key":"322_CR7","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2230.2008.03024.x","volume":"34","author":"JH Kunishige","year":"2009","unstructured":"Kunishige JH, McDonald H, Alvarez G, Johnson M, Prieto V, Duvic M. Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients. Clin Exp Dermatol. 2009;34(5):576\u201381.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"322_CR8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaad.2015.09.013","volume":"74","author":"I Wieser","year":"2016","unstructured":"Wieser I, Oh CW, Talpur R, Duvic M. Lymphomatoid papulosis: treatment response and associated lymphomas in a study of 180 patients. J Am Acad Dermatol. 2016;74(1):59\u201367.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"322_CR9","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/0190-9622(91)70220-V","volume":"25","author":"P Wolf","year":"1991","unstructured":"Wolf P, Cerroni L, Smolle J, Kerl H. PUVA-induced lymphomatoid papulosis in a patient with mycosis fungoides. J Am Acad Dermatol. 1991;25(2):422\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"322_CR10","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0190-9622(96)90442-9","volume":"34","author":"EC Vonderheid","year":"1996","unstructured":"Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol. 1996;34(3):470\u201381.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"322_CR11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000068451","volume":"206","author":"RA Krathen","year":"2003","unstructured":"Krathen RA, Ward S, Duvic M. Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology. 2003;206(2):142\u20137.","journal-title":"Dermatology"},{"issue":"32","key":"322_CR12","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","volume":"33","author":"M Duvic","year":"2015","unstructured":"Duvic M, Tetzlaff MT, Gangar P, et al. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33(32):3759\u201365.","journal-title":"J Clin Oncol"},{"issue":"6","key":"322_CR13","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/0190-9622(93)70140-O","volume":"28","author":"R Willemze","year":"1993","unstructured":"Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol. 1993;28(6):973\u201380.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"322_CR14","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0190-9622(03)02484-8","volume":"49","author":"HL Liu","year":"2003","unstructured":"Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. 2003;49(6):1049\u201358.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"322_CR15","first-page":"667","volume":"145","author":"DK Woo","year":"2009","unstructured":"Woo DK, Jones CR, Vanoli-Storz MN, et al. Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Arch Dermatol. 2009;145(6):667\u201374.","journal-title":"Arch Dermatol"},{"key":"322_CR16","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","volume":"124","author":"ER Parrilla Castillar","year":"2014","unstructured":"Parrilla Castillar ER, Jaffe ES, Said J, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124:1473\u201380.","journal-title":"Blood"},{"key":"322_CR17","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/leu.2008.320","volume":"23","author":"AL Feldman","year":"2009","unstructured":"Feldman AL, Law M, Remstein ED, et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia. 2009;23:574\u201380.","journal-title":"Leukemia"},{"key":"322_CR18","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/PAS.0b013e318282d01e","volume":"37","author":"LJ Karai","year":"2013","unstructured":"Karai LJ, Kadin ME, Hsi ED, et al. Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. Am J Surg Pathol. 2013;37:1173\u201381.","journal-title":"Am J Surg Pathol"},{"issue":"15","key":"322_CR19","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2011-05-351346","volume":"118","author":"W Kempf","year":"2011","unstructured":"Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118(15):4024\u201335.","journal-title":"Blood"},{"issue":"18","key":"322_CR20","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","volume":"119","author":"SM Horwitz","year":"2012","unstructured":"Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012;119(18):4115\u201322.","journal-title":"Blood"},{"issue":"4","key":"322_CR21","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.det.2008.05.008","volume":"26","author":"F Gallardo","year":"2008","unstructured":"Gallardo F, Pujol RM. Subcutaneous panniculitic-like T-cell lymphoma and other primary cutaneous lymphomas with prominent subcutaneous tissue involvement. Dermatol Clin. 2008;26(4):529\u201340. viii.","journal-title":"Dermatol Clin"},{"issue":"2","key":"322_CR22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.humpath.2003.09.015","volume":"35","author":"M Takeshita","year":"2004","unstructured":"Takeshita M, Okamura S, Oshiro Y, et al. Clinicopathologic differences between 22 cases of CD56-negative and CD56-positive subcutaneous panniculitis-like lymphoma in Japan. Hum Pathol. 2004;35(2):231\u20139.","journal-title":"Hum Pathol"},{"issue":"11","key":"322_CR23","first-page":"1372","volume":"89","author":"M Paulli","year":"2004","unstructured":"Paulli M, Berti E. Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II. Haematologica. 2004;89(11):1372\u201388.","journal-title":"Haematologica"},{"issue":"Suppl 6","key":"322_CR24","doi-asserted-by":"crossref","first-page":"vi149","DOI":"10.1093\/annonc\/mdt242","volume":"24","author":"R Willemze","year":"2013","unstructured":"Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M, Group EGW. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol : Off J Eur Soc Med Oncol \/ ESMO. 2013;24 Suppl 6:vi149\u201354.","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol \/ ESMO"},{"key":"322_CR25","unstructured":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Vol 2. Lyon, France: International Agency for Research on Cancer; 2008."},{"issue":"6","key":"322_CR26","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/cncr.20502","volume":"101","author":"RS Go","year":"2004","unstructured":"Go RS, Wester SM. Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature. Cancer. 2004;101(6):1404\u201313.","journal-title":"Cancer"},{"issue":"6","key":"322_CR27","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/00000421-199412000-00003","volume":"17","author":"K Matsue","year":"1994","unstructured":"Matsue K, Itoh M, Tsukuda K, Miyazaki K, Kokubo T. Successful treatment of cytophagic histiocytic panniculitis with modified CHOP-E. Cyclophosphamide, adriamycin, vincristine, predonisone, and etoposide. Am J Clin Oncol. 1994;17(6):470\u20134.","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"322_CR28","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/sj.bmt.1705527","volume":"38","author":"E Perez-Persona","year":"2006","unstructured":"Perez-Persona E, Mateos-Mazon JJ, Lopez-Villar O, et al. Complete remission of subcutaneous panniculitic T-cell lymphoma after allogeneic transplantation. Bone Marrow Transplant. 2006;38(12):821\u20132.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"322_CR29","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1080\/10428190600783619","volume":"47","author":"M Ichii","year":"2006","unstructured":"Ichii M, Hatanaka K, Imakita M, Ueda Y, Kishino B, Tamaki T. Successful treatment of refractory subcutaneous panniculitis-like T-cell lymphoma with allogeneic peripheral blood stem cell transplantation from HLA-mismatched sibling donor. Leuk lymphoma. 2006;47(10):2250\u20132.","journal-title":"Leuk lymphoma"},{"issue":"3","key":"322_CR30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.12659\/AOT.882007","volume":"16","author":"L Yuan","year":"2011","unstructured":"Yuan L, Sun L, Bo J, et al. Durable remission in a patient with refractory subcutaneous panniculitis-like T-cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation through withdrawal of cyclosporine. Annal Transplant : Q Pol Transplant Soc. 2011;16(3):135\u20138.","journal-title":"Annal Transplant : Q Pol Transplant Soc"},{"issue":"6","key":"322_CR31","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1034\/j.1600-0609.2003.00058.x","volume":"70","author":"HY Mukai","year":"2003","unstructured":"Mukai HY, Okoshi Y, Shimizu S, et al. Successful treatment of a patient with subcutaneous panniculitis-like T-cell lymphoma with high-dose chemotherapy and total body irradiation. Eur J Haematol. 2003;70(6):413\u20136.","journal-title":"Eur J Haematol"},{"issue":"1","key":"322_CR32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clml.2011.06.016","volume":"12","author":"N Mehta","year":"2012","unstructured":"Mehta N, Wayne AS, Kim YH, et al. Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations. Clin Lymphoma Myeloma Leuk. 2012;12(1):20\u20135.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"322_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-4362.1996.tb01606.x","volume":"35","author":"CY Wang","year":"1996","unstructured":"Wang CY, Su WP, Kurtin PJ. Subcutaneous panniculitic T-cell lymphoma. Int J Dermatol. 1996;35(1):1\u20138.","journal-title":"Int J Dermatol"},{"issue":"3","key":"322_CR34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3816\/CLM.2002.n.024","volume":"3","author":"JS Papenfuss","year":"2002","unstructured":"Papenfuss JS, Aoun P, Bierman PJ, Armitage JO. Subcutaneous panniculitis-like T-cell lymphoma: presentation of 2 cases and observations. Clin lymphoma. 2002;3(3):175\u201380.","journal-title":"Clin lymphoma"},{"issue":"3","key":"322_CR35","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.annder.2008.07.061","volume":"136","author":"G Springinsfeld","year":"2009","unstructured":"Springinsfeld G, Guillaume JC, Boeckler P, Tortel MC, Cribier B. Two cases of subcutaneous panniculitis-like T-cell lymphoma (CD4- CD8+ CD56-). Ann Dermatol Venereol. 2009;136(3):264\u20138.","journal-title":"Ann Dermatol Venereol"},{"issue":"4","key":"322_CR36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4143\/crt.2011.43.4.255","volume":"43","author":"HR Jung","year":"2011","unstructured":"Jung HR, Yun SY, Choi JH, Bae SH, Ryoo HM, Kum YS. Cyclosporine in Relapsed Subcutaneous Panniculitis-like T-Cell Lymphoma after Autologous Hematopoietic Stem Cell Transplantation. Cancer Res Treat : Off J Korean Cancer Assoc. 2011;43(4):255\u20139.","journal-title":"Cancer Res Treat : Off J Korean Cancer Assoc"},{"issue":"3","key":"322_CR37","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4143\/crt.2014.46.3.312","volume":"46","author":"WS Lee","year":"2014","unstructured":"Lee WS, Hwang JH, Kim MJ, et al. Cyclosporine A as a primary treatment for panniculitis-like T cell lymphoma: a case with a long-term remission. Cancer Res Treat : Off J Korean Cancer Assoc. 2014;46(3):312\u20136.","journal-title":"Cancer Res Treat : Off J Korean Cancer Assoc"},{"issue":"8","key":"322_CR38","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3816\/CLM.2007.n.040","volume":"7","author":"T Hathaway","year":"2007","unstructured":"Hathaway T, Subtil A, Kuo P, Foss F. Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell lymphoma. Clin Lymphoma Myeloma. 2007;7(8):541\u20135.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"11","key":"322_CR39","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1097\/PAS.0b013e31826a5038","volume":"36","author":"J Guitart","year":"2012","unstructured":"Guitart J, Weisenburger DD, Subtil A, et al. Cutaneous gammadelta T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. Am J Surg Pathol. 2012;36(11):1656\u201365.","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"322_CR40","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2002-05-1597","volume":"101","author":"JR Toro","year":"2003","unstructured":"Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood. 2003;101(9):3407\u201312.","journal-title":"Blood"},{"issue":"7","key":"322_CR41","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/cas.12439","volume":"105","author":"Y Takahashi","year":"2014","unstructured":"Takahashi Y, Takata K, Kato S, et al. Clinicopathological analysis of 17 primary cutaneous T-cell lymphoma of the gammadelta phenotype from Japan. Cancer Sci. 2014;105(7):912\u201323.","journal-title":"Cancer Sci"},{"issue":"8","key":"322_CR42","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/PAS.0b013e31822067d1","volume":"35","author":"A Garcia-Herrera","year":"2011","unstructured":"Garcia-Herrera A, Song JY, Chuang SS, et al. Nonhepatosplenic gammadelta T-cell lymphomas represent a spectrum of aggressive cytotoxic T-cell lymphomas with a mainly extranodal presentation. Am J Surg Pathol. 2011;35(8):1214\u201325.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"322_CR43","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1309\/AJCPQGVLTZQ77VFF","volume":"138","author":"CM Magro","year":"2012","unstructured":"Magro CM, Wang X. Indolent primary cutaneous gamma\/delta T-cell lymphoma localized to the subcutaneous panniculus and its association with atypical lymphocytic lobular panniculitis. Am J Clin Pathol. 2012;138(1):50\u20136.","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"322_CR44","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jaad.2011.07.043","volume":"67","author":"A Nofal","year":"2012","unstructured":"Nofal A, Abdel-Mawla MY, Assaf M, Salah E. Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma: proposed diagnostic criteria and therapeutic evaluation. J Am Acad Dermatol. 2012;67(4):748\u201359.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"322_CR45","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/his.12371","volume":"67","author":"A Robson","year":"2015","unstructured":"Robson A, Assaf C, Bagot M, et al. Aggressive epidermotropic cutaneous CD8+ lymphoma: a cutaneous lymphoma with distinct clinical and pathological features. Report of an EORTC Cutaneous Lymphoma Task Force Workshop. Histopathology. 2015;67(4):425\u201341.","journal-title":"Histopathology"},{"key":"322_CR46","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0002-9440(10)65144-9","volume":"155","author":"E Berti","year":"1999","unstructured":"Berti E, Tomasini D, Vermeer MH, Meijer CJ, Alessi E, Willemze R. Primary cutaneous CD8-positive epidermotropic cytotoxic T-cell lymphomas: a distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol. 1999;155:483\u201392.","journal-title":"Am J Pathol"},{"issue":"1","key":"322_CR47","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1600-0560.2009.01278.x","volume":"37","author":"H Beltraminelli","year":"2010","unstructured":"Beltraminelli H, Mullegger R, Cerroni L. Indolent CD8+ lymphoid proliferation of the ear: a phenotypic variant of the small-medium pleomorphic cutaneous T-cell lymphoma? J Cutan Pathol. 2010;37(1):81\u20134.","journal-title":"J Cutan Pathol"},{"issue":"2","key":"322_CR48","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1600-0560.2010.01647.x","volume":"38","author":"BL Swick","year":"2011","unstructured":"Swick BL, Baum CL, Venkat AP, Liu V. Indolent CD8+ lymphoid proliferation of the ear: report of two cases and review of the literature. J Cutan Pathol. 2011;38(2):209\u201315.","journal-title":"J Cutan Pathol"},{"issue":"2","key":"322_CR49","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaad.2009.02.035","volume":"62","author":"RH Gormley","year":"2010","unstructured":"Gormley RH, Hess SD, Anand D, Junkins-Hopkins J, Rook AH, Kim EJ. Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma. J Am Acad Dermatol. 2010;62(2):300\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"322_CR50","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3109\/10428194.2014.938331","volume":"56","author":"E James","year":"2015","unstructured":"James E, Sokhn JG, Gibson JF, et al. CD4\u2009+\u2009primary cutaneous small\/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature. Leuk lymphoma. 2015;56(4):951\u20137.","journal-title":"Leuk lymphoma"},{"issue":"1","key":"322_CR51","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/PAS.0b013e31818e52fe","volume":"33","author":"SM Rodriguez Pinilla","year":"2009","unstructured":"Rodriguez Pinilla SM, Roncador G, Rodriguez-Peralto JL, et al. Primary cutaneous CD4+ small\/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers. Am J Surg Pathol. 2009;33(1):81\u201390.","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"322_CR52","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/DAD.0b013e31819f19bb","volume":"31","author":"H Beltraminelli","year":"2009","unstructured":"Beltraminelli H, Leinweber B, Kerl H, Cerroni L. Primary cutaneous CD4+ small-\/medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases. Am J Dermatopathol. 2009;31(4):317\u201322.","journal-title":"Am J Dermatopathol"},{"issue":"6","key":"322_CR53","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2002-07-1960","volume":"102","author":"MW Bekkenk","year":"2003","unstructured":"Bekkenk MW, Vermeer MH, Jansen PM, et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood. 2003;102(6):2213\u20139.","journal-title":"Blood"},{"issue":"6","key":"322_CR54","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/modpathol.2008.40","volume":"21","author":"KL Grogg","year":"2008","unstructured":"Grogg KL, Jung S, Erickson LA, McClure RF, Dogan A. Primary cutaneous CD4-positive small\/medium-sized pleomorphic T-cell lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior. Mod Pathol : Off J U S Can Acad Pathol Inc. 2008;21(6):708\u201315.","journal-title":"Mod Pathol : Off J U S Can Acad Pathol Inc"},{"issue":"6","key":"322_CR55","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/11595500-000000000-00000","volume":"12","author":"VL Williams","year":"2011","unstructured":"Williams VL, Torres-Cabala CA, Duvic M. Primary cutaneous small- to medium-sized CD4+ pleomorphic T-cell lymphoma: a retrospective case series and review of the provisional cutaneous lymphoma category. Am J Clin Dermatol. 2011;12(6):389\u2013401.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"322_CR56","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jaad.2010.07.028","volume":"65","author":"CL Baum","year":"2011","unstructured":"Baum CL, Link BK, Neppalli VT, Swick BL, Liu V. Reappraisal of the provisional entity primary cutaneous CD4+ small\/medium pleomorphic T-cell lymphoma: a series of 10 adult and pediatric patients and review of the literature. J Am Acad Dermatol. 2011;65(4):739\u201348.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"322_CR57","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1600-0560.2009.01448.x","volume":"37","author":"R Suchak","year":"2010","unstructured":"Suchak R, O\u2019Connor S, McNamara C, Robson A. Indolent CD8-positive lymphoid proliferation on the face: part of the spectrum of primary cutaneous small-\/medium-sized pleomorphic T-cell lymphoma or a distinct entity? J Cutan Pathol. 2010;37(9):977\u201381.","journal-title":"J Cutan Pathol"},{"issue":"21","key":"322_CR58","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","volume":"113","author":"PT Bradford","year":"2009","unstructured":"Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064\u201373.","journal-title":"Blood"},{"issue":"3","key":"322_CR59","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jdermsci.2007.09.001","volume":"48","author":"R Dummer","year":"2007","unstructured":"Dummer R, Asagoe K, Cozzio A, et al. Recent advances in cutaneous lymphomas. J Dermatol Sci. 2007;48(3):157\u201367.","journal-title":"J Dermatol Sci"},{"issue":"12","key":"322_CR60","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1200\/JCO.2006.09.6396","volume":"25","author":"NJ Senff","year":"2007","unstructured":"Senff NJ, Hoefnagel JJ, Jansen PM, et al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol : Off J Am Soc Clin Oncol. 2007;25(12):1581\u20137.","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"2","key":"322_CR61","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","volume":"110","author":"YH Kim","year":"2007","unstructured":"Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(2):479\u201384.","journal-title":"Blood"},{"issue":"9","key":"322_CR62","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/archderm.141.9.1139","volume":"141","author":"JJ Hoefnagel","year":"2005","unstructured":"Hoefnagel JJ, Vermeer MH, Jansen PM, et al. Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases. Arch Dermatol. 2005;141(9):1139\u201345.","journal-title":"Arch Dermatol"},{"issue":"3","key":"322_CR63","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2230.2004.01692.x","volume":"30","author":"E Zendri","year":"2005","unstructured":"Zendri E, Venturi C, Ricci R, Giordano G, De Panfilis G. Primary cutaneous plasmacytoma: a role for a triggering stimulus? Clin Exp Dermatol. 2005;30(3):229\u201331.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"322_CR64","first-page":"512","volume":"53","author":"SA May","year":"2005","unstructured":"May SA, Netto G, Domiati-Saad R, Kasper C. Cutaneous lymphoid hyperplasia and marginal zone B-cell lymphoma following vaccination. J Am Acad Dermatol. 2005;53(3):512\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"9760","key":"322_CR65","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0140-6736(10)62241-6","volume":"377","author":"E Aberer","year":"2011","unstructured":"Aberer E, Fingerle V, Wutte N, Fink-Puches R, Cerroni L. Within European margins. Lancet. 2011;377(9760):178.","journal-title":"Lancet"},{"issue":"8","key":"322_CR66","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1600-0560.1997.tb01318.x","volume":"24","author":"L Cerroni","year":"1997","unstructured":"Cerroni L, Zochling N, Putz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol. 1997;24(8):457\u201361.","journal-title":"J Cutan Pathol"},{"issue":"9","key":"322_CR67","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/00000478-200009000-00012","volume":"24","author":"JR Goodlad","year":"2000","unstructured":"Goodlad JR, Davidson MM, Hollowood K, et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland. Am J Surg Pathol. 2000;24(9):1279\u201385.","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"322_CR68","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1634\/theoncologist.2011-0108","volume":"16","author":"M Ponzoni","year":"2011","unstructured":"Ponzoni M, Ferreri AJ, Mappa S, et al. Prevalence of Borrelia burgdorferi infection in a series of 98 primary cutaneous lymphomas. Oncologist. 2011;16(11):1582\u20138.","journal-title":"Oncologist"},{"issue":"10","key":"322_CR69","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1034\/j.1600-0560.2001.281002.x","volume":"28","author":"GS Wood","year":"2001","unstructured":"Wood GS, Kamath NV, Guitart J, et al. Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States. J Cutan Pathol. 2001;28(10):502\u20137.","journal-title":"J Cutan Pathol"},{"issue":"6","key":"322_CR70","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1046\/j.1365-2133.2002.04961.x","volume":"147","author":"O Servitje","year":"2002","unstructured":"Servitje O, Gallardo F, Estrach T, et al. Primary cutaneous marginal zone B-cell lymphoma: a clinical, histopathological, immunophenotypic and molecular genetic study of 22 cases. Br J Dermatol. 2002;147(6):1147\u201358.","journal-title":"Br J Dermatol"},{"issue":"12","key":"322_CR71","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1097\/PAS.0b013e3181f72835","volume":"34","author":"JT Edinger","year":"2010","unstructured":"Edinger JT, Kant JA, Swerdlow SH. Cutaneous marginal zone lymphomas have distinctive features and include 2 subsets. Am J Surg Pathol. 2010;34(12):1830\u201341.","journal-title":"Am J Surg Pathol"},{"issue":"Suppl","key":"322_CR72","first-page":"S38","volume":"125","author":"JH Cho-Vega","year":"2006","unstructured":"Cho-Vega JH, Vega F, Rassidakis G, Medeiros LJ. Primary cutaneous marginal zone B-cell lymphoma. Am J Clin Pathol. 2006;125(Suppl):S38\u201349.","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"322_CR73","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/modpathol.2008.30","volume":"21","author":"X Xie","year":"2008","unstructured":"Xie X, Sundram U, Natkunam Y, et al. Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphoma. Mod Pathol. 2008;21(6):653\u20139.","journal-title":"Mod Pathol"},{"issue":"3","key":"322_CR74","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1200\/JCO.20.3.647","volume":"20","author":"I Mirza","year":"2002","unstructured":"Mirza I, Macpherson N, Paproski S, et al. Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features. J Clin Oncol. 2002;20(3):647\u201355.","journal-title":"J Clin Oncol"},{"issue":"9","key":"322_CR75","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1001\/archderm.143.9.1144","volume":"143","author":"F Grange","year":"2007","unstructured":"Grange F, Beylot-Barry M, Courville P, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol. 2007;143(9):1144\u201350.","journal-title":"Arch Dermatol"},{"issue":"11","key":"322_CR76","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/archderm.1996.03890350042008","volume":"132","author":"MH Vermeer","year":"1996","unstructured":"Vermeer MH, Geelen FA, van Haselen CW, et al. Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group [see comments]. Arch Dermatol. 1996;132(11):1304\u20138.","journal-title":"Arch Dermatol"},{"issue":"6","key":"322_CR77","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1200\/JCO.1998.16.6.2080","volume":"16","author":"FA Geelen","year":"1998","unstructured":"Geelen FA, Vermeer MH, Meijer CJ, et al. bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related. J Clin Oncol. 1998;16(6):2080\u20135.","journal-title":"J Clin Oncol"},{"issue":"10","key":"322_CR78","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood-2003-08-2726","volume":"103","author":"F Grange","year":"2004","unstructured":"Grange F, Petrella T, Beylot-Barry M, et al. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. Blood. 2004;103(10):3662\u20138.","journal-title":"Blood"},{"issue":"6","key":"322_CR79","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1365-2133.2003.05649.x","volume":"149","author":"JJ Hoefnagel","year":"2003","unstructured":"Hoefnagel JJ, Vermeer MH, Jansen PM, Fleuren GJ, Meijer CJ, Willemze R. Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance. Br J Dermatol. 2003;149(6):1183\u201391.","journal-title":"Br J Dermatol"},{"issue":"3","key":"322_CR80","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.0303-6987.2005.00298.x","volume":"32","author":"U Sundram","year":"2005","unstructured":"Sundram U, Kim Y, Mraz-Gernhard S, Hoppe R, Natkunam Y, Kohler S. Expression of the bcl-6 and MUM1\/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study. J Cutan Pathol. 2005;32(3):227\u201334.","journal-title":"J Cutan Pathol"},{"issue":"10","key":"322_CR81","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/sj.leu.2403501","volume":"18","author":"B Streubel","year":"2004","unstructured":"Streubel B, Simonitsch-Klupp I, Mullauer L, et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia. 2004;18(10):1722\u20136.","journal-title":"Leukemia"},{"issue":"4","key":"322_CR82","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00000478-200604000-00015","volume":"30","author":"B Streubel","year":"2006","unstructured":"Streubel B, Scheucher B, Valencak J, et al. Molecular cytogenetic evidence of t(14;18)(IGH;BCL2) in a substantial proportion of primary cutaneous follicle center lymphomas. Am J Surg Pathol. 2006;30(4):529\u201336.","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"322_CR83","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1182\/blood.V95.12.3922","volume":"95","author":"L Cerroni","year":"2000","unstructured":"Cerroni L, Arzberger E, Putz B, et al. Primary cutaneous follicle center cell lymphoma with follicular growth pattern. Blood. 2000;95(12):3922\u20138.","journal-title":"Blood"},{"key":"322_CR84","doi-asserted-by":"crossref","unstructured":"Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2005;105(9):3671\u20138.","DOI":"10.1182\/blood-2004-04-1594"},{"issue":"2","key":"322_CR85","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1200\/JCO.2005.02.0842","volume":"24","author":"R Dijkman","year":"2006","unstructured":"Dijkman R, Tensen CP, Jordanova ES, et al. Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma. J Clin Oncol. 2006;24(2):296\u2013305.","journal-title":"J Clin Oncol"},{"issue":"1","key":"322_CR86","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.0022-202X.2004.22720.x","volume":"123","author":"C Hallermann","year":"2004","unstructured":"Hallermann C, Kaune KM, Gesk S, et al. Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas. J Investig Dermatol. 2004;123(1):213\u20139.","journal-title":"J Investig Dermatol"},{"key":"322_CR87","unstructured":"NCCN guidelines. http:\/\/www.nccn.org ."},{"issue":"5","key":"322_CR88","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","volume":"112","author":"NJ Senff","year":"2008","unstructured":"Senff NJ, Noordijk EM, Kim YH, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008;112(5):1600\u20139.","journal-title":"Blood"},{"issue":"1","key":"322_CR89","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijrobp.2008.06.1918","volume":"74","author":"KJ Neelis","year":"2009","unstructured":"Neelis KJ, Schimmel EC, Vermeer MH, Senff NJ, Willemze R, Noordijk EM. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys. 2009;74(1):154\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"322_CR90","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/10428190500399698","volume":"47","author":"A Cozzio","year":"2006","unstructured":"Cozzio A, Kempf W, Schmid-Meyer R, et al. Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma. Leuk lymphoma. 2006;47(5):865\u20139.","journal-title":"Leuk lymphoma"},{"issue":"9","key":"322_CR91","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.4049\/jimmunol.177.9.6227","volume":"177","author":"A Audig\u00e9","year":"2006","unstructured":"Audig\u00e9 A, Urosevic M, Schlaepfer E, et al. Anti-HIV state but not apoptosis depends on IFN signature in CD4+ T cells. J Immunol. 2006;177(9):6227\u201337.","journal-title":"J Immunol"},{"issue":"1","key":"322_CR92","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2133.2010.09798.x","volume":"163","author":"A Perry","year":"2010","unstructured":"Perry A, Vincent BJ, Parker SR. Intralesional corticosteroid therapy for primary cutaneous B-cell lymphoma. Br J Dermatol. 2010;163(1):223\u20135.","journal-title":"Br J Dermatol"},{"issue":"2","key":"322_CR93","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0733-8635(18)30169-4","volume":"12","author":"G Burg","year":"1994","unstructured":"Burg G, Dummer R, Kerl H. Classification of cutaneous lymphomas. Dermatol Clin. 1994;12(2):213\u20137.","journal-title":"Dermatol Clin"},{"issue":"4","key":"322_CR94","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1440-0960.1998.tb01487.x","volume":"39","author":"KC Wong","year":"1998","unstructured":"Wong KC, Weller PA. Primary cutaneous B cell lymphoma: outcomes and treatment. Australas J Dermatol. 1998;39(4):261\u20134.","journal-title":"Australas J Dermatol"},{"issue":"3","key":"322_CR95","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/archderm.136.3.374","volume":"136","author":"L Heinzerling","year":"2000","unstructured":"Heinzerling L, Dummer R, Kempf W, Schmid MH, Burg G. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. Arch Dermatol. 2000;136(3):374\u20138.","journal-title":"Arch Dermatol"},{"issue":"4","key":"322_CR96","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1600-0609.2006.00720.x","volume":"77","author":"MC Kyrtsonis","year":"2006","unstructured":"Kyrtsonis MC, Siakantaris MP, Kalpadakis C, et al. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. Eur J Haematol. 2006;77(4):300\u20133.","journal-title":"Eur J Haematol"},{"issue":"5","key":"322_CR97","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaad.2005.01.093","volume":"52","author":"R Fink-Puches","year":"2005","unstructured":"Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol. 2005;52(5):847\u201353.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"322_CR98","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1080\/10428190600688099","volume":"47","author":"E Gitelson","year":"2006","unstructured":"Gitelson E, Al-Saleem T, Millenson M, Lessin S, Smith MR. Cutaneous B-cell lymphoma responds to rituximab: a report of five cases and a review of the literature. Leuk lymphoma. 2006;47(9):1902\u20137.","journal-title":"Leuk lymphoma"},{"issue":"8","key":"322_CR99","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/1097-0142(20001015)89:8<1835::AID-CNCR26>3.0.CO;2-H","volume":"89","author":"LM Heinzerling","year":"2000","unstructured":"Heinzerling LM, Urbanek M, Funk JO, et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer. 2000;89(8):1835\u201344.","journal-title":"Cancer"},{"issue":"6","key":"322_CR100","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000241302","volume":"22","author":"A Farkas","year":"2009","unstructured":"Farkas A, Kemeny L, French LE, Dummer R. New and experimental skin-directed therapies for cutaneous lymphomas. Skin Pharmacol Physiol. 2009;22(6):322\u201334.","journal-title":"Skin Pharmacol Physiol"},{"issue":"4","key":"322_CR101","first-page":"391","volume":"16","author":"EA Coors","year":"2006","unstructured":"Coors EA, Schuler G, Von Den Driesch P. Topical imiquimod as treatment for different kinds of cutaneous lymphoma. Eur J Dermatol : EJD. 2006;16(4):391\u20133.","journal-title":"Eur J Dermatol : EJD"},{"issue":"3","key":"322_CR102","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2005.04.043","volume":"53","author":"MA Bogle","year":"2005","unstructured":"Bogle MA, Riddle CC, Triana EM, Jones D, Duvic M. Primary cutaneous B-cell lymphoma. J Am Acad Dermatol. 2005;53(3):479\u201384.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"322_CR103","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1067\/mjd.2002.120475","volume":"47","author":"F Grange","year":"2002","unstructured":"Grange F, Wechsler J, Guillaume JC, et al. Borrelia burgdorferi-associated lymphocytoma cutis simulating a primary cutaneous large B-cell lymphoma. J Am Acad Dermatol. 2002;47(4):530\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"322_CR104","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000051735","volume":"203","author":"GF Hofbauer","year":"2001","unstructured":"Hofbauer GF, Kessler B, Kempf W, Nestle FO, Burg G, Dummer R. Multilesional primary cutaneous diffuse large B-cell lymphoma responsive to antibiotic treatment. Dermatology. 2001;203(2):168\u201370.","journal-title":"Dermatology"},{"issue":"2","key":"322_CR105","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0190-9622(97)80405-7","volume":"36","author":"B Kutting","year":"1997","unstructured":"Kutting B, Bonsmann G, Metze D, Luger TA, Cerroni L. Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. J Am Acad Dermatol. 1997;36(2):311\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"14","key":"322_CR106","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1200\/JCO.2007.13.6929","volume":"26","author":"DO Persky","year":"2008","unstructured":"Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol : Off J Am Soc Clin Oncol. 2008;26(14):2258\u201363.","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"6","key":"322_CR107","first-page":"753","volume":"20","author":"M Fenot","year":"2010","unstructured":"Fenot M, Quereux G, Brocard A, Renaut JJ, Dreno B. Rituximab for primary cutaneous diffuse large B-cell lymphoma-leg type. Eur J Dermatol : EJD. 2010;20(6):753\u20137.","journal-title":"Eur J Dermatol : EJD"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-016-0322-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-016-0322-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-016-0322-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T08:20:37Z","timestamp":1655540437000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-016-0322-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,21]]},"references-count":107,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["322"],"URL":"https:\/\/doi.org\/10.1007\/s11899-016-0322-5","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,21]]}}}